ClinicalTrials.gg
RecruitingNCT07177339VIGILANTUpdated Nov 17, 2026

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

A Phase 3 interventional study of Depemokimab and Placebo in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Recruiting at 293 sites in 25 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 17, 2026First sites in 12 new countriesPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,196
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline — 7 open to participants now, 8 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · GlaxoSmithKline.

Planned enrollment
16th of 236
1,196 · median 101
Started
2025
with 3 others
Phase 3
65 of 276
5 open now
Registered
272nd of 276
by date

Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 16th largest by planned enrollment of the 236 interventional ones that give a count, is one of 4 that started in 2025, is one of 65 in phase 3, and was the 272nd registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, or all of them as a file.
02

Study summary

Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • Depemokimab
  • Chronic Obstructive Pulmonary Disorder
  • COPD
  • Type 2 inflammation
  • Eosinophilic phenotype
  • Exacerbation
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or eligible female participants
  • Eosinophilic phenotype measured using Blood Eosinophil Count (BEC)
  • Moderate to severe , defined as

    • A clinically documented history of COPD for at least 1 year
    • A post-salbutamol (FEV1)/Forced vital capacity (FVC) ratio of less than (\<)0.70 and a post-salbutamol FEV1 greater than (>)30 percent (%) and \<80% predicted normal values
  • Elevated risk for exacerbations, defined as

    • A well-documented history of only 1 moderate COPD exacerbation in the prior 12 months and
    • The presence of risk factors for future exacerbations/deterioration such as:
    • Modified Medical Research Council (mMRC) dyspnea score >= 2
    • COPD Assessment Test (CAT) >= 15
    • Post-bronchodilator FEV1 \< 50% predicted
    • Chronic bronchitis
  • Smoking status: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years at Screening.
  • Dual (Inhaled (ICS)+ Long-acting beta2-adrenergic receptor agonist [LABA] or LABA+ Long-acting muscarinic receptor antagonist [LAMA]) or triple (ICS+LABA+LAMA) inhaler therapy as assessed by the investigator for at least 3 months
  • (BMI) >=16 kilograms per square meter (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

  • The Investigator must judge that is the primary diagnosis accounting for the clinical manifestations of lung disease, and clinical manifestations of lung disease where primary diagnosis is not COPD are excluded

    • Participants with a current or prior physician diagnosis of asthma
    • Participants with childhood asthma are permitted, provided that childhood asthma has resolved before 18 years of age and has not recurred
  • Other lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease.
  • COPD severity: Participants with more than one moderate exacerbation or severe exacerbation in the past 12 months prior to Visit 1
  • COPD stability: Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Visit 1
  • Lung resection: Participants with a history of, or plan for lung volume reduction surgery/endobronchial valve procedure
  • Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1
  • Chronic hypercapnia requiring non-invasive positive pressure ventilation (NIPPV) use including Bi-Level Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP) are excluded
  • Continuous oxygen: Participants requiring oxygen supplementation for COPD
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,196 participants (estimated)

Study arms

  • Experimental
    Depemokimab

    Participants with Chronic Obstructive Pulmonary Disorder (COPD) with Type 2 inflammation will receive Depemokimab in combination with existing Standard of Care (SoC).

    Drug: Depemokimab

  • Experimental
    Placebo

    Participants with COPD with Type 2 inflammation will receive matching Placebo in combination with existing SoC.

    Drug: Placebo

Interventions

  • Depemokimab will be administered.

  • DrugPlacebo

    Matching placebo will be administered.

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Moderate/Severe Exacerbations

    Moderate exacerbations are defined as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (that is greater than or equal to \[\>=\] 24 hours) or result in death. The frequency of moderate/ severe exacerbations expressed as an annualized rate of moderate or severe exacerbations will be reported.

    Time frame: From Baseline Up to Week 156

Secondary outcomes

  1. Time to First Moderate/Severe Exacerbation

    Moderate exacerbations are defined as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (that is greater than or equal to (\>=) 24 hours) or result in death.

    Time frame: From Baseline Up to Week 156

  2. Change from Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52

    The SGRQ total score will be measured using the SGRQ for COPD \[SGRQ-C\]. The SGRQ-C is a 40-item participant questionnaire designed to measure health impairment by addressing the frequency of respiratory symptoms (questions 1-7) and the participants current state (questions 8-14). The questions are designed to be completed by the participant. The total score will be calculated on 0-100 rating scale and scores expressed as a percentage of overall impairment. Higher scores indicate greater impairment of health.

    Time frame: From Baseline up to Week 52

  3. Change from Baseline in Evaluating Respiratory Symptoms (E-RS): COPD Total Score at Week 52

    E-RS: COPD consists of 11 items from the 14-item Exacerbations of Chronic Pulmonary Disease Tool - Patient Reported Outcomes (EXACT) instrument. E-RS: COPD is intended to capture information related to the respiratory symptoms of COPD, that is, breathlessness, cough, sputum production, chest congestion, and chest tightness. The E-RS: COPD has a scoring range of 0 to 40, higher scores indicate more severe symptoms.

    Time frame: From Baseline up to Week 52

07

Study locations

291 of 293 sites recruiting
  • GSK Investigational Site
    Sheffield, Alabama 35660, United States
    Recruiting
  • GSK Investigational Site
    Tucson, Arizona 85715-3850, United States
    Recruiting
  • GSK Investigational Site
    Escondido, California 92025, United States
    Recruiting
  • GSK Investigational Site
    Long Beach, California 90805, United States
    Recruiting
  • GSK Investigational Site
    Newport Beach, California 92663, United States
    Recruiting
  • GSK Investigational Site
    San Jose, California 95128-2654, United States
    Recruiting
  • GSK Investigational Site
    Lakewood, Colorado 80228-1813, United States
    Recruiting
  • GSK Investigational Site
    Altamonte Springs, Florida 32701, United States
    Recruiting
  • GSK Investigational Site
    Brandon, Florida 33511, United States
    Recruiting
  • GSK Investigational Site
    Crystal River, Florida 34429-8722, United States
    Recruiting
  • GSK Investigational Site
    Doral, Florida 33172, United States
    Recruiting
  • GSK Investigational Site
    Greenacres City, Florida 33467, United States
    Recruiting
  • GSK Investigational Site
    Hialeah, Florida 33012, United States
    Recruiting
  • GSK Investigational Site
    Hialeah, Florida 33016, United States
    Recruiting
  • GSK Investigational Site
    Hollywood, Florida 33024, United States
    Recruiting
  • GSK Investigational Site
    Loxahatchee Groves, Florida 33470, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33125, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33126, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33176, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33176, United States
    Recruiting
  • GSK Investigational Site
    Miami Lakes, Florida 33016, United States
    Recruiting
  • GSK Investigational Site
    Miami Lakes, Florida 33016, United States
    Recruiting
  • GSK Investigational Site
    Naples, Florida 34102, United States
    Recruiting
  • GSK Investigational Site
    Orlando, Florida 32825-4457, United States
    Recruiting
  • GSK Investigational Site
    Tampa, Florida 33614, United States
    Recruiting
  • GSK Investigational Site
    Adairsville, Georgia 30103, United States
    Recruiting
  • GSK Investigational Site
    Cordele, Georgia 31015, United States
    Recruiting
  • GSK Investigational Site
    Dunwoody, Georgia 30350, United States
    Recruiting
  • GSK Investigational Site
    Boise, Idaho 83702, United States
    Recruiting
  • GSK Investigational Site
    Peoria, Illinois 85381, United States
    Recruiting
  • GSK Investigational Site
    Indianapolis, Indiana 46268, United States
    Recruiting
  • GSK Investigational Site
    Bowling Green, Kentucky 42101, United States
    Recruiting
  • GSK Investigational Site
    Baton Rouge, Louisiana 70816, United States
    Recruiting
  • GSK Investigational Site
    Lake Charles, Louisiana 70605, United States
    Recruiting
  • GSK Investigational Site
    Metairie, Louisiana 70006-2904, United States
    Recruiting
  • GSK Investigational Site
    Shreveport, Louisiana 71105, United States
    Recruiting
  • GSK Investigational Site
    Bangor, Maine 04401, United States
    Recruiting
  • GSK Investigational Site
    Fall River, Massachusetts 02723-1511, United States
    Recruiting
  • GSK Investigational Site
    Allen Park, Michigan 48101, United States
    Recruiting
  • GSK Investigational Site
    Clarkston, Michigan 48346, United States
    Recruiting
  • GSK Investigational Site
    Dearborn, Michigan 48126-1813, United States
    Recruiting
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
    Recruiting
  • GSK Investigational Site
    Missoula, Montana 59808, United States
    Recruiting
  • GSK Investigational Site
    Henderson, Nevada 89052-5015, United States
    Recruiting
  • GSK Investigational Site
    Las Vegas, Nevada 89123-2874, United States
    Recruiting
  • GSK Investigational Site
    Reno, Nevada 89502, United States
    Recruiting
  • GSK Investigational Site
    Sewell, New Jersey 08080, United States
    Recruiting
  • GSK Investigational Site
    New Windsor, New York 12553, United States
    Recruiting
  • GSK Investigational Site
    North Massapequa, New York 11758, United States
    Recruiting
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • GSK Investigational Site
    Winston-Salem, North Carolina 27157, United States
    Recruiting
  • GSK Investigational Site
    Kettering, Ohio 45439-2201, United States
    Recruiting
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73134-4003, United States
    Recruiting
  • GSK Investigational Site
    DuBois, Pennsylvania 15801-2277, United States
    Recruiting
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
    Recruiting
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15236, United States
    Recruiting
  • GSK Investigational Site
    West Chester, Pennsylvania 19380, United States
    Recruiting
  • GSK Investigational Site
    Greenville, South Carolina 29607, United States
    Recruiting
  • GSK Investigational Site
    Rock Hill, South Carolina 29732, United States
    Recruiting
  • GSK Investigational Site
    Knoxville, Tennessee 37919, United States
    Recruiting
  • GSK Investigational Site
    Dallas, Texas 75254, United States
    Recruiting
  • GSK Investigational Site
    DeSoto, Texas 75115, United States
    Recruiting
  • GSK Investigational Site
    Greenville, Texas 75401-7854, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77008, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77008, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77018, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77058-2805, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77089, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77090, United States
    Recruiting
  • GSK Investigational Site
    Katy, Texas 77494, United States
    Recruiting
  • GSK Investigational Site
    McAllen, Texas 78504, United States
    Recruiting
  • GSK Investigational Site
    Mesquite, Texas 75149, United States
    Recruiting
  • GSK Investigational Site
    Pearland, Texas 77584, United States
    Recruiting
  • GSK Investigational Site
    Stafford, Texas 77477, United States
    Recruiting
  • GSK Investigational Site
    Lobos, Buenos Aires, Argentina
    Recruiting
  • GSK Investigational Site
    Buenos Aires, C1426ABP, Argentina
    Recruiting
  • GSK Investigational Site
    Ciudad Autonoma de Bueno, C1414AIF, Argentina
    Recruiting
  • GSK Investigational Site
    Córdoba, 5000, Argentina
    Recruiting
  • GSK Investigational Site
    Córdoba, X5000DCE, Argentina
    Recruiting
  • GSK Investigational Site
    La Plata, B1900AVG, Argentina
    Recruiting
  • GSK Investigational Site
    Mar del Plata, B7602DCK, Argentina
    Recruiting
  • GSK Investigational Site
    Paraná, 3100, Argentina
    Recruiting
  • GSK Investigational Site
    Rosario, S2002OJN, Argentina
    Recruiting
  • GSK Investigational Site
    Rosario Provincia de Santa FE, 2013, Argentina
    Recruiting
  • GSK Investigational Site
    San Miguel de Tucumán, T4000IFL, Argentina
    Recruiting
  • GSK Investigational Site
    San Miguel de Tucumán, T4000, Argentina
    Recruiting
  • GSK Investigational Site
    Santa Fe, S3000ASF, Argentina
    Recruiting
  • GSK Investigational Site
    Santa Fe, S3000, Argentina
    Recruiting
  • GSK Investigational Site
    Coffs Harbour, New South Wales 2450, Australia
    Recruiting
  • GSK Investigational Site
    Mandurah, Western Australia 6210, Australia
    Recruiting
  • GSK Investigational Site
    Kortrijk, 8500, Belgium
    Recruiting
  • GSK Investigational Site
    Leuven, 3000, Belgium
    Recruiting
  • GSK Investigational Site
    Mont Gaston, 5530, Belgium
    Recruiting
  • GSK Investigational Site
    Belo Horizonte, Minas Gerais 30150-221, Brazil
    Recruiting
  • GSK Investigational Site
    Porto Alegre, 90610000, Brazil
    Recruiting
  • GSK Investigational Site
    São Paulo, 05403-000, Brazil
    Recruiting
  • GSK Investigational Site
    Sofia, Grad Sofia 1233, Bulgaria
    Recruiting
  • GSK Investigational Site
    Haskovo, 6300, Bulgaria
    Recruiting
  • GSK Investigational Site
    Montana, 3400, Bulgaria
    Recruiting

Showing the first 100 of 293 sites across 25 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Apr 2029, 41 months after the start.

Of 109 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 41 months is above that.

Counting every sponsor, half of 142 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Sep 17, 2025
StartActual
Oct 20, 2025
Primary completionEst.
Apr 2, 2029
CompletionEst.
Jun 4, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
175 sites added, 3 sites removed — first sites in Argentina, Belgium, Brazil, Chile, Denmark and 7 more
All 12 countries

Argentina, Belgium, Brazil, Chile, Denmark, France, Hungary, Italy, Netherlands, Romania, South Korea, Taiwan

Show 175 added (34 United States, 33 Japan, 15 Germany, 14 Argentina, 9 United Kingdom, 8 South Korea, 8 Spain, 7 France, 6 Israel, 4 Denmark, 4 Poland, 3 Belgium, 3 Brazil, 3 Bulgaria, 3 Canada, 3 Greece, 3 Italy, 3 Romania, 3 Taiwan, 2 China, 2 Hungary, 2 Netherlands, 1 Australia, 1 Chile, 1 New Zealand)
  • GSK Investigational Site · Sheffield, United States
  • GSK Investigational Site · Tucson, United States
  • GSK Investigational Site · Escondido, United States
  • GSK Investigational Site · Long Beach, United States
  • GSK Investigational Site · San Jose, United States
  • GSK Investigational Site · Altamonte Springs, United States
  • GSK Investigational Site · Hialeah, United States
  • GSK Investigational Site · Loxahatchee Groves, United States
  • GSK Investigational Site · Miami, United States
  • GSK Investigational Site · Miami Lakes, United States
  • GSK Investigational Site · Naples, United States
  • GSK Investigational Site · Tampa, United States
  • GSK Investigational Site · Adairsville, United States
  • GSK Investigational Site · Peoria, United States
  • GSK Investigational Site · Indianapolis, United States
  • GSK Investigational Site · Baton Rouge, United States
  • GSK Investigational Site · Metairie, United States
  • GSK Investigational Site · Fall River, United States
  • GSK Investigational Site · Detroit, United States
  • GSK Investigational Site · Missoula, United States
  • GSK Investigational Site · Sewell, United States
  • GSK Investigational Site · New Windsor, United States
  • GSK Investigational Site · North Massapequa, United States
  • GSK Investigational Site · Winston-Salem, United States
  • GSK Investigational Site · Kettering, United States
  • GSK Investigational Site · Oklahoma City, United States
  • GSK Investigational Site · Philadelphia, United States
  • GSK Investigational Site · Pittsburgh, United States
  • GSK Investigational Site · Pittsburgh, United States
  • GSK Investigational Site · Houston, United States
  • …and 145 more on the registry record
Show 3 removed
  • GSK Investigational Site · Edmond, United States
  • GSK Investigational Site · Spearwood, Australia
  • GSK Investigational Site · Frankfurt, Germany
Nov 17, 2026
Primary completion
Apr 30, 2029→Apr 2, 2029
Nov 17, 2026
Study completion
Jun 8, 2029→Jun 4, 2029
Nov 17, 2026
Site contacts
Changed at 9 sites. See the sites
Show 9 sites
  • GSK Investigational Site · Brandon, United StatesContact person changed (no phone or email listed)
  • GSK Investigational Site · Houston, United StatesContact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)
  • GSK Investigational Site · Changsha, ChinaContact person changed (no phone or email listed)
  • GSK Investigational Site · Hohhot, ChinaContact person changed (no phone or email listed)
  • GSK Investigational Site · Zunyi, ChinaContact person changed (no phone or email listed)
  • GSK Investigational Site · Frankfurt, GermanyContact person changed (no phone or email listed)
  • GSK Investigational Site · München, GermanyContact person changed (no phone or email listed)
  • GSK Investigational Site · Thessaloniki, GreeceContact person changed (no phone or email listed)
  • GSK Investigational Site · Gifu, JapanContact person changed (no phone or email listed)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    175 sites added, 3 sites removed — first sites in Argentina, Belgium, Brazil, Chile, Denmark and 7 more
    All 12 countries

    Argentina, Belgium, Brazil, Chile, Denmark, France, Hungary, Italy, Netherlands, Romania, South Korea, Taiwan

    Show 175 added (34 United States, 33 Japan, 15 Germany, 14 Argentina, 9 United Kingdom, 8 South Korea, 8 Spain, 7 France, 6 Israel, 4 Denmark, 4 Poland, 3 Belgium, 3 Brazil, 3 Bulgaria, 3 Canada, 3 Greece, 3 Italy, 3 Romania, 3 Taiwan, 2 China, 2 Hungary, 2 Netherlands, 1 Australia, 1 Chile, 1 New Zealand)
    • GSK Investigational Site · Sheffield, United States
    • GSK Investigational Site · Tucson, United States
    • GSK Investigational Site · Escondido, United States
    • GSK Investigational Site · Long Beach, United States
    • GSK Investigational Site · San Jose, United States
    • GSK Investigational Site · Altamonte Springs, United States
    • GSK Investigational Site · Hialeah, United States
    • GSK Investigational Site · Loxahatchee Groves, United States
    • GSK Investigational Site · Miami, United States
    • GSK Investigational Site · Miami Lakes, United States
    • GSK Investigational Site · Naples, United States
    • GSK Investigational Site · Tampa, United States
    • GSK Investigational Site · Adairsville, United States
    • GSK Investigational Site · Peoria, United States
    • GSK Investigational Site · Indianapolis, United States
    • GSK Investigational Site · Baton Rouge, United States
    • GSK Investigational Site · Metairie, United States
    • GSK Investigational Site · Fall River, United States
    • GSK Investigational Site · Detroit, United States
    • GSK Investigational Site · Missoula, United States
    • GSK Investigational Site · Sewell, United States
    • GSK Investigational Site · New Windsor, United States
    • GSK Investigational Site · North Massapequa, United States
    • GSK Investigational Site · Winston-Salem, United States
    • GSK Investigational Site · Kettering, United States
    • GSK Investigational Site · Oklahoma City, United States
    • GSK Investigational Site · Philadelphia, United States
    • GSK Investigational Site · Pittsburgh, United States
    • GSK Investigational Site · Pittsburgh, United States
    • GSK Investigational Site · Houston, United States
    • …and 145 more on the registry record
    Show 3 removed
    • GSK Investigational Site · Edmond, United States
    • GSK Investigational Site · Spearwood, Australia
    • GSK Investigational Site · Frankfurt, Germany
    Primary completion Apr 30, 2029→Apr 2, 2029
    Study completion Jun 8, 2029→Jun 4, 2029
    Site contacts Changed at 9 sites. See the sites
    Show 9 sites
    • GSK Investigational Site · Brandon, United StatesContact person changed (no phone or email listed)
    • GSK Investigational Site · Houston, United StatesContact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    • GSK Investigational Site · Changsha, ChinaContact person changed (no phone or email listed)
    • GSK Investigational Site · Hohhot, ChinaContact person changed (no phone or email listed)
    • GSK Investigational Site · Zunyi, ChinaContact person changed (no phone or email listed)
    • GSK Investigational Site · Frankfurt, GermanyContact person changed (no phone or email listed)
    • GSK Investigational Site · München, GermanyContact person changed (no phone or email listed)
    • GSK Investigational Site · Thessaloniki, GreeceContact person changed (no phone or email listed)
    • GSK Investigational Site · Gifu, JapanContact person changed (no phone or email listed)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07177339
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 17, 2025
Start date
Oct 20, 2025
Primary completion
Apr 2, 2029 (estimated)
Completion
Jun 4, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Depemokimab

Start the discussion